Press release, 31 March 2022 at 9:00 (EEST)

Commercialization of Nightingale’s technology is still progressing on a broad front. The story combining the company’s high risks and potential has, in our opinion, only strengthened after the IPO. Pricing of future promises has fallen dramatically as the time horizon has shortened on the market, which is also reflected in Nightingale. Concrete supporting points for the company's valuation can in the short term already be found in the balance sheet focusing on cash (2022e P/B 1.2x). 

Nightingale Health Plc Half-year report 1 July 2021 - 31 December 2021 (unaudited)

Nightingale Health Group's Half-year report: Progressing faster than expected in line with strategy

Company Release, 24 February 2022 at 9:00 a.m. (EET)

This release is a summary of Nightingale Health Plc's Half-year report from period 1 July 2021 - 31 December 2021. The full Half-year report is attached to this release.

Numbers presented in brackets refer to corresponding year-on-year period unless otherwise stated.

Press release, 16 February 2022 at 12 p.m. (EET)

Nightingale Health Plc will publish its half-year report for July - December 2021 on 24 February 2022 at around 9 a.m. EET. The materials will be made available soon after publication at www.nightingalehealth.com/investors.